OBJECTIVE: To assess the importance of MAPT variant p.A152T in the risk of synucleinopathies. METHODS: In this case-control study, we screened a large global series of patients and controls, and assessed associations between p.A152T and disease risk. We included 3,229 patients with clinical Parkinson disease (PD), 442 with clinical dementia with Lewy bodies (DLB), 181 with multiple system atrophy (MSA), 832 with pathologically confirmed Lewy body disease (LBD), and 2,456 healthy controls. RESULTS: The minor allele frequencies (MAF) in clinical PD cases (0.28%) and in controls (0.2%) were not found to be significantly different (odds ratio [OR] 1.37, 95% confidence interval [CI] 0.63-2.98, p = 0.42). However, a significant association was observed with clinical DLB (MAF 0.68%, OR 5.76, 95% CI 1.62-20.51, p = 0.007) and LBD (MAF 0.42%, OR 3.55, 95% CI 1.04-12.17, p = 0.04). Additionally, p.A152T was more common in patients with MSA compared to controls (MAF 0.55%, OR 4.68, 95% CI 0.85-25.72, p = 0.08) but this was not statistically significant and therefore should be interpreted with caution. CONCLUSIONS: Overall, our findings suggest that MAPT p.A152T is a rare low penetrance variant likely associated with DLB that may be influenced by coexisting LBD and AD pathology. Given the rare nature of the variant, further studies with greater sample size are warranted and will help to fully explain the role of p.A152T in the pathogenesis of the synucleinopathies.

From the Departments of Neuroscience Mayo Clinic Scottsdale AZ

Neurology. 2015 Nov 10;85(19):1728. doi: 10.1212/WNL.0000000000002138. PubMed

Zobrazit více v PubMed

McCann H, Stevens CH, Cartwright H, Halliday GM. Alpha-synucleinopathy phenotypes. Parkinsonism Relat Disord 2014;20(suppl 1):S62–S67. PubMed

Jenner P, Morris HR, Robbins TW, et al. Parkinson's disease: the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinson Dis 2013;3:1–11. PubMed PMC

Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014;46:989–993. PubMed PMC

Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. Plos Genet 2012;8:e1002548. PubMed PMC

Sharma M, Ioannidis JP, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012;79:659–667. PubMed PMC

Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702–705. PubMed

Pittman AM, Fung HC, de Silva R. Untangling the tau gene association with neurodegenerative disorders. Hum Mol Genet 2006;15(Spec 2):R188–R195. PubMed

Kovacs GG, Wohrer A, Strobel T, Botond G, Attems J, Budka H. Unclassifiable tauopathy associated with an A152T variation in MAPT exon 7. Clin Neuropathol 2011;30:3–10. PubMed

Coppola G, Chinnathambi S, Lee JJ, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012;21:3500–3512. PubMed PMC

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184. PubMed PMC

McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–1872. PubMed

Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–676. PubMed PMC

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259. PubMed

McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124. PubMed

Labbe C, Soto-Ortolaza AI, Rayaprolu S, et al. Investigating the role of FUS exonic variants in essential tremor. Parkinsonism Relat Disord 2013;19:755–757. PubMed PMC

Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–575. PubMed PMC

Skipper L, Wilkes K, Toft M, et al. Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet 2004;75:669–677. PubMed PMC

Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet 2014;23:6139–6146. PubMed PMC

Vilarino-Guell C, Soto-Ortolaza AI, Rajput A, et al. MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology 2011;76:670–672. PubMed PMC

Kara E, Ling H, Pittman AM, et al. The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging 2012;33:2231.e7–2231.e14. PubMed PMC

Moussaud S, Jones DR, Moussaud-Lamodiere EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegen 2014;9:43. PubMed PMC

Muntane G, Dalfo E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 2008;152:913–923. PubMed

Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002;104:7–11. PubMed

Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300:636–640. PubMed

Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy